Statin-induced myositis: a commonly encountered or rare side effect?

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Toxicology

Background:

• Statins are primary agents for lowering LDL cholesterol in cardiovascular disease.
• While generally safe, statins carry a risk of myopathy, potentially leading to rhabdomyolysis.
• Understanding statin interactions, injury mechanisms, and toxicity is crucial for patient safety.

Purpose of the Study:

• To review current evidence on statin interactions.
• To examine the mechanisms of statin-induced myopathy and toxicity.
• To inform clinical practice regarding statin prescribing and patient monitoring.

Main Methods:

• Literature review of current evidence on statin interactions and toxicity.
• Analysis of proposed mechanisms for statin myotoxicity.
• Examination of clinical outcomes and risk factors associated with statin use.

Main Results:

• Significant statin-induced myopathy occurs in less than 0.5% of patients.
• Side effects can be dose-dependent, influenced by drug interactions (cytochrome P450, glucuronidation), or comorbidities.
• Proposed mechanisms include intracellular cholesterol depletion and interference with oxidative phosphorylation, though not fully defined.

Conclusions:

• High-risk patients on statins often take multiple medications, increasing interaction risks.
• Rhabdomyolysis from myalgia/myositis is rare but can be fatal if ignored.
• Physicians must be vigilant for potential statin risks and educate patients on reporting symptoms.